Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Op Gr: COVID-19 Rapid Research FO - Clinical Mgmt/Health System Interventions

McMaster University

$303,658.00

Venous Thrombosis Virtual Surveillance in COVID (VVIRTUOSO)

EF 2020-21

Résumé
COVID-19 increases the risk of blood clots especially in patients who are admitted to hospital. Reports show a high rate of venous thrombosis (blood clots in the veins) affecting 3% of COVID-19 patients admitted to hospital and 11% to 70% of those who have life-threatening illness. This is higher than hospitalized patients with other medical illnesses. Venous thrombosis includes blood clots in the lungs (pulmonary embolism) and deep vein thrombosis (DVT). It is one of the most common preventable causes of death and disability associated with hospitalization. Most cases of venous thrombosis occur after hospital discharge and can be fatal if not diagnosed and treated promptly. The risk of venous thrombosis in patients with COVID-19 after discharge from hospital is not currently known. They are likely at high risk due to incomplete recovery, reduced mobility, older age and other medical problems. The overall goal of the VVIRTUOSO study determine the rate of venous thrombosis after hospital discharge in 500 patients with COVID-19 using a virtual monitoring program at 12 sites in Canada and the United States. We will also explore factors that increase the likelihood of venous thrombosis. As part of this study, we will also assess VTE awareness and patient-reported quality of the monitoring program (quality of communication and patient satisfaction). Our multidisciplinary team includes researchers, clinicians, patient partners and collaborators Thrombosis Canada (www.thrombosiscanada.ca) and the CanVECTOR Network (www.canvector.ca). We have the necessary experience, existing research network infrastructure, and knowledge translation mechanisms to successfully complete this study and disseminate the results rapidly and widely.
Programme
Op Gr: COVID-19 Rapid Research FO - Clinical Mgmt/Health System Interventions
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
430032
Name
Siegal Deborah M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
COVID-19 Rapid Research - Clinical Management & Health System Interventions
Projecttitle
Venous Thrombosis Virtual Surveillance in COVID (VVIRTUOSO)
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$303,658
Cihrequipment2
$0
Programname2
Op Gr: COVID-19 Rapid Research FO - Clinical Mgmt/Health System Interventions
Keyworddelim
Awareness; Covid-19; Hospital Discharge; Incidence; Quality Of Communication; Risk Factors; Venous Thromboembolism
Abstract
COVID-19 increases the risk of blood clots especially in patients who are admitted to hospital. Reports show a high rate of venous thrombosis (blood clots in the veins) affecting 3% of COVID-19 patients admitted to hospital and 11% to 70% of those who have life-threatening illness. This is higher than hospitalized patients with other medical illnesses. Venous thrombosis includes blood clots in the lungs (pulmonary embolism) and deep vein thrombosis (DVT). It is one of the most common preventable causes of death and disability associated with hospitalization. Most cases of venous thrombosis occur after hospital discharge and can be fatal if not diagnosed and treated promptly. The risk of venous thrombosis in patients with COVID-19 after discharge from hospital is not currently known. They are likely at high risk due to incomplete recovery, reduced mobility, older age and other medical problems. The overall goal of the VVIRTUOSO study determine the rate of venous thrombosis after hospital discharge in 500 patients with COVID-19 using a virtual monitoring program at 12 sites in Canada and the United States. We will also explore factors that increase the likelihood of venous thrombosis. As part of this study, we will also assess VTE awareness and patient-reported quality of the monitoring program (quality of communication and patient satisfaction). Our multidisciplinary team includes researchers, clinicians, patient partners and collaborators Thrombosis Canada (www.thrombosiscanada.ca) and the CanVECTOR Network (www.canvector.ca). We have the necessary experience, existing research network infrastructure, and knowledge translation mechanisms to successfully complete this study and disseminate the results rapidly and widely.
Competitiondate
202005
Approvedterm2
1 yr 0 mth
Pinamesdelim
Siegal, Deborah M; Carrier, Marc
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $303,658~ $0~